Table 5 Small-molecule inhibitors of the METTL3-14 in preclinical and clinical development
From: Methyltransferase-like proteins in cancer biology and potential therapeutic targeting
No. | Inhibitors | PubChem CID | MW (Da) | Clinical trials title | Phase | Status | ClinicalTrials.gov identifier |
|---|---|---|---|---|---|---|---|
1 | Quercetin | 5,280,343 | 302.23 | Effect of Quercetin in Prevention and Treatment of Oral Mucositis (Chemotherapy Induced Oral Mucositis) | Phase 2 | Completed | NCT01732393 |
Quercetin Chemoprevention for Squamous Cell Carcinoma in Patients With Fanconi Anemia | Phase 2 | Recruiting | NCT03476330 | ||||
Reduce Senescence and Improve Frailty in Adult Survivors of Childhood Cancer | Phase 2 | Â | NCT04733534 | ||||
Therapeutic Efficacy of Quercetin Versus Its Encapsulated Nanoparticle on Tongue Squamous Cell Carcinoma Cell Line | Phase 2 | Â | NCT05456022 | ||||
Effect of Quercetin on Green Tea Polyphenol Uptake in Prostate Tissue From Patients With Prostate Cancer Undergoing Surgery | Phase 1 | Completed | NCT01912820 | ||||
Trial of Quercetin in the Treatment and Prevention of Chemotherapy-induced Neuropathic Pain in Cancer Patients | Early Phase 1 | Withdrawn | NCT02989129 | ||||
Sulindac and Plant Compounds in Preventing Colon Cancer | N/A | Terminated | NCT00003365 | ||||
2 | Delicaflavone | – | |||||
3 | STM2457 | 155,167,581 | 444.5 | Create 2020-12-19 | |||
4 | UZH1a | 154,815,692 | 558.7 | Create 2020-11-24 | |||
5 | Eltrombopag | 135,449,332 | 442.5 | Identification and Validation of Biomarkers for Breast Cancer Resistance Protein (BCRP) | Phase 1 | Recruiting | NCT04542382 |
Study Impact on Outcome of Eltrombopag in Elderly Patients With Acute Myeloid Leukemia Receiving Induction Chemotherapy | Phase 2 | Active, not recruiting | NCT03603795 | ||||
Pilot Trial of Eltrombopag in Patients Undergoing Chemotherapy for Malignant Solid Tumors | Phase 1 | Recruiting | NCT04485416 | ||||
Eltrombopag Treatment in Patients With Prolonged BM Toxicity After CART | Phase 2 | Recruiting | NCT05286164 | ||||
Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL) | Phase 2 | Completed | NCT01168921 | ||||
Eltrombopag for Chemotherapy-induced Thrombocytopenia | Phase 2 | Recruiting | NCT04600960 | ||||
Eltrombopag in Elderly Acute Myelogenous Leukemia (AML) | Phase1/Phase2 | Terminated | NCT01113502 | ||||
A Study of Eltrombopag in Patients With CMML and Thrombocytopenia | Phase1/Phase2 | Completed | NCT02323178 | ||||
Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease | Phase 4 | Unknown | NCT03844360 | ||||
A Safety and Efficacy Study of Eltrombopag in Subjects With AML | Phase 2 | Completed | NCT01890746 | ||||
Eltrombopag Used in Thrombocytopenia After Consolidation Therapy in AML | Phase2/Phase3 | Unknown | NCT03701217 | ||||
Dose Finding Study Of Oral Eltrombopag In Patients With Sarcoma Receiving Adriamycin And Ifosfamide | Phase 1 | Completed | NCT00358540 | ||||
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia | Phase 2 | Completed | NCT01440374 | ||||
A Randomized Placebo-controlled Phase 2 Study of Decitabine With or Without Eltrombopag in AML Patients | Phase 2 | Unknown | NCT02446145 | ||||
Eltrombopag in Thrombocytopenic Chronic Lymphocytic Leukemia (CLL) Patients (CLL2S Study of GCLLSG) | Phase1/Phase2 | Terminated | NCT01397149 | ||||
6 | CDIBA derivative | – | |||||